Top CFO Executive Search Firm in Hyderabad for Pharma & Biotech — 2026

As India's pharma and life-sciences capital, Hyderabad makes the pharma CFO a discipline of regulated-manufacturing cost, R&D capital and global-client finance. Across Genome Valley and the surrounding bulk-drug, formulations and vaccine clusters, a CFO must run cost and capex for USFDA- and WHO-GMP-grade facilities, manage R&D capitalisation, milestone and grant accounting and dilution in biotech and biosimilars, and command the client-contract and capacity economics of CRO and CDMO businesses serving global pharma under audit. The defining scarcity is the finance leader who is comfortable with the science and the long cycle, can fund and steward development and capacity, and holds regulator-grade financial controls.

Compensation blends a cash base with milestone- and approval-linked incentives and, in venture- or listed-biotech settings, equity tied to development milestones; bulk-drug and formulations CFOs are more cash-led with capex-and-cost focus. The brief sets which applies. The stakeholder map runs from scientific and R&D leadership and investors to auditors and global pharma clients. References reach to investors, auditors and scientific-finance peers, because the question that decides these mandates — can this CFO fund the science and hold the controls — is answered by those who have watched them through a cycle.